Page last updated: 2024-11-08

convallatoxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

convallatoxin: PI: *CONVALLARIA (73-79) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

convallatoxin : A cardenolide glycoside that consists of strophanthidin having a 6-deoxy-alpha-L-mannopyranosyl (L-rhamnosyl) group attached at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441852
CHEMBL ID399336
CHEBI ID27663
SCHEMBL ID308440
MeSH IDM0040659

Synonyms (50)

Synonym
jy264vir1y ,
unii-jy264vir1y
rhamnoside, strophanthidin-3, alpha-l-
card-20(22)-enolide, 3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3beta,5beta)-
mannopyranoside, strophanthidin-3,6-deoxy-, alpha-l-
nsc 407808
hsdb 3475
einecs 208-086-3
strophanthidin alpha-l-rhamnoside
CHEBI:27663 ,
3beta-(6-deoxy-alpha-l-mannopyranosyloxy)-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enolide
strophanthidin, 3-(6-deoxy-alpha-l-mannopyranoside)
3beta-(alpha-l-rhamnopyranosyloxy)-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enolide
3beta-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,14-dihydroxy-19-oxo-5beta-card-20(22)-enolide
(3beta,5beta)-3-((6-deoxy-alpha-l-mannopyranosyl)oxy)-5,14-dihydroxy-19-oxo-card-20(22)-enolide
5beta,14beta-dihydroxy-19-oxo-3beta[(alpha-l-rhamnopyranosyl)oxy]card-20,22-enolide
convallotoxin
korglykon
corglycone
convallaton
convallaotoxin
convallatoxoside
corglycon
corglykon
508-75-8
strophanthidin 3-o-alpha-l-rhamnoside
C08858
convallatoxin
convallatoxin, >=65%
CHEMBL399336
(3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-3-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
LMST01120013
strophanthidin .alpha.-l-rhamnoside
card-20(22)-enolide, 3-((6-deoxy-.alpha.-l-mannopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3.beta.,5.beta.)-
convallatoxin [who-dd]
convallatoxin [mi]
SCHEMBL308440
AC-35137
bdbm50480587
(3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-3-[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde
card-20(22)-enolide, 3-[(6-deoxyhexopyranosyl)oxy]-5,14-dihydroxy-19-oxo-
Q2996215
CS-0022681
HY-N2453
convallopan
convalpur
convapur
DTXSID90862073
MS-30077
AKOS040760350

Research Excerpts

Overview

Convallatoxin (CNT) is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. It has both anti-inflammatory and anti-proliferative properties.

ExcerptReferenceRelevance
"Convallatoxin (CNT) is a natural cardiac glycoside extracted from lily of the valley ( Convallaria majalis ). "( Involvement of monocyte-derived extracellular vesicle-associated tissue factor activity in convallatoxin-induced hypercoagulability.
Kasuda, S; Kudo, R; Morimoto, M; Sakata, A; Takabayashi, Y; Tatsumi, K; Terazawa, I; Yuui, K, 2023
)
2.57
"Convallatoxin (CNT) is a natural cardiac glycoside with anti-inflammatory pharmacological properties."( Convallatoxin Promotes M2 Macrophage Polarization to Attenuate Atherosclerosis Through PPARγ-Integrin α
Fang, Z; Han, J; Lin, J; Lin, Y; Peng, W; Shi, X; Xiao, F; Xu, X; Zhang, Y; Zhao, L; Zhou, Y, 2021
)
2.79
"Convallatoxin (CNT) is a cardiac glycoside isolated from Adonis amurensis Regel et Radde and has both anti-inflammatory and anti-proliferative properties. "( Convallatoxin protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB signaling through activation of PPARγ.
Jin, CH; Jin, X; Li, MY; Ma, J; Piao, LX; Wang, JY; Wang, Z; Xing, Y; Xu, GH; Zhang, ZH; Zuo, HX, 2019
)
3.4

Compound-Compound Interactions

ExcerptReferenceRelevance
" Selected cardiac glycosides were tested in combination with four clinically relevant cytotoxic drugs (5-fluorouracil, oxaliplatin, cisplatin, irinotecan)."( Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
Bohlin, L; Felth, J; Fryknäs, M; Gullbo, J; Lindskog, M; Rickardson, L; Rosén, J; Wickström, M, 2009
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
alpha-L-rhamnoside
19-oxo steroid
14beta-hydroxy steroidA 14-hydroxy steroid in which the hydroxy group has a beta-configuration.
5beta-hydroxy steroid
steroid lactone
steroid aldehydeAny steroid substituted by a formyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hypoxia-inducible factor 1-alphaHomo sapiens (human)EC50 (µMol)0.02000.02001.29905.0100AID421968
Endothelial PAS domain-containing protein 1Homo sapiens (human)EC50 (µMol)0.02000.02000.93303.3000AID421968
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (98)

Processvia Protein(s)Taxonomy
positive regulation of chemokine-mediated signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of signaling receptor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to reactive oxygen speciesHypoxia-inducible factor 1-alphaHomo sapiens (human)
angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular glucose homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural crest cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial to mesenchymal transitionHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic placenta developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
B-1 B cell homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of endothelial cell proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
heart loopingHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
chondrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
glandular epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
connective tissue replacement involved in inflammatory response wound healingHypoxia-inducible factor 1-alphaHomo sapiens (human)
outflow tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
cardiac ventricle morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactate metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of glycolytic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular iron ion homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
signal transductionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuroblast proliferationHypoxia-inducible factor 1-alphaHomo sapiens (human)
lactationHypoxia-inducible factor 1-alphaHomo sapiens (human)
visual learningHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to iron ionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of gene expressionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of epithelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to muscle activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
axonal transport of mitochondrionHypoxia-inducible factor 1-alphaHomo sapiens (human)
neural fold elevation formationHypoxia-inducible factor 1-alphaHomo sapiens (human)
cerebral cortex developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of bone mineralizationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of TOR signalingHypoxia-inducible factor 1-alphaHomo sapiens (human)
intracellular oxygen homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of chemokine productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transforming growth factor beta2 productionHypoxia-inducible factor 1-alphaHomo sapiens (human)
collagen metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to oxidative stressHypoxia-inducible factor 1-alphaHomo sapiens (human)
embryonic hemopoiesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusHypoxia-inducible factor 1-alphaHomo sapiens (human)
hemoglobin biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of erythrocyte differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of angiogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of growthHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
muscle cell cellular homeostasisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of hormone biosynthetic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
digestive tract morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of nitric-oxide synthase activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
neuron apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
elastin metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
intestinal epithelial cell maturationHypoxia-inducible factor 1-alphaHomo sapiens (human)
epithelial cell differentiation involved in mammary gland alveolus developmentHypoxia-inducible factor 1-alphaHomo sapiens (human)
iris morphogenesisHypoxia-inducible factor 1-alphaHomo sapiens (human)
retina vasculature development in camera-type eyeHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of thymocyte apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to interleukin-1Hypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to hypoxiaHypoxia-inducible factor 1-alphaHomo sapiens (human)
dopaminergic neuron differentiationHypoxia-inducible factor 1-alphaHomo sapiens (human)
mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
hypoxia-inducible factor-1alpha signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
cellular response to virusHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of mitophagyHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
positive regulation of miRNA transcriptionHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of aerobic respirationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of protein neddylationHypoxia-inducible factor 1-alphaHomo sapiens (human)
negative regulation of mesenchymal cell apoptotic processHypoxia-inducible factor 1-alphaHomo sapiens (human)
regulation of transcription by RNA polymerase IIHypoxia-inducible factor 1-alphaHomo sapiens (human)
response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
angiogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
embryonic placenta developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
blood vessel remodelingEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of heart rateEndothelial PAS domain-containing protein 1Homo sapiens (human)
epithelial cell maturationEndothelial PAS domain-containing protein 1Homo sapiens (human)
response to oxidative stressEndothelial PAS domain-containing protein 1Homo sapiens (human)
mitochondrion organizationEndothelial PAS domain-containing protein 1Homo sapiens (human)
signal transductionEndothelial PAS domain-containing protein 1Homo sapiens (human)
visual perceptionEndothelial PAS domain-containing protein 1Homo sapiens (human)
erythrocyte differentiationEndothelial PAS domain-containing protein 1Homo sapiens (human)
lung developmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
norepinephrine metabolic processEndothelial PAS domain-containing protein 1Homo sapiens (human)
mRNA transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
surfactant homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
myoblast fate commitmentEndothelial PAS domain-containing protein 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEndothelial PAS domain-containing protein 1Homo sapiens (human)
cellular response to hypoxiaEndothelial PAS domain-containing protein 1Homo sapiens (human)
positive regulation of cold-induced thermogenesisEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of protein neddylationEndothelial PAS domain-containing protein 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription repressor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription coactivator bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificHypoxia-inducible factor 1-alphaHomo sapiens (human)
p53 bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
DNA-binding transcription factor activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear receptor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
enzyme bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein kinase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein domain specific bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
ubiquitin protein ligase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
histone deacetylase bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein heterodimerization activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
Hsp90 protein bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
E-box bindingHypoxia-inducible factor 1-alphaHomo sapiens (human)
transcription regulator activator activityHypoxia-inducible factor 1-alphaHomo sapiens (human)
sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription coactivator bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
protein heterodimerization activityEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear bodyHypoxia-inducible factor 1-alphaHomo sapiens (human)
nuclear speckHypoxia-inducible factor 1-alphaHomo sapiens (human)
motile ciliumHypoxia-inducible factor 1-alphaHomo sapiens (human)
axon cytoplasmHypoxia-inducible factor 1-alphaHomo sapiens (human)
chromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
euchromatinHypoxia-inducible factor 1-alphaHomo sapiens (human)
protein-containing complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexHypoxia-inducible factor 1-alphaHomo sapiens (human)
nucleoplasmEndothelial PAS domain-containing protein 1Homo sapiens (human)
cytosolEndothelial PAS domain-containing protein 1Homo sapiens (human)
nuclear speckEndothelial PAS domain-containing protein 1Homo sapiens (human)
chromatinEndothelial PAS domain-containing protein 1Homo sapiens (human)
transcription regulator complexEndothelial PAS domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID492115Cardiotonic activity in guinea pig right ventricular muscles assessed as minimum positive inotropic effective concentration causing myocardial contraction2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID471515Cytotoxicity against human HCT116 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID1072829Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID421968Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID492116Cardiotonic activity in guinea pig left atrial muscles assessed as maximum positive inotropic effective concentration causing myocardial contraction relative to basal level2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID421976Inhibition of HIF1alpha protein expression in wild type human U251 cells under hypoxic condition at 0.025 uM treated 8 hrs before hypoxia induction2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421978Reduction in VEGF mRNA expression in wild type human U251 cells under hypoxic condition after 8 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID1072832Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID421971Growth inhibition of human U251 cells stably transfected with pGL3 plasmid after 24 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421969Inhibition of HIF1 activation in human U251 cells stably transfected in pGL3 plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID1072827Cytotoxicity against human CAKI-1 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID471511Cytotoxicity against human CC20 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID421981Reduction in carbonic anhydrase 9 mRNA expression in wild type human U251 cells under hypoxic condition at 0.1 uM after 16 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID1072833Cytotoxicity against human KBVIN cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID767901Cytotoxicity against human NIH-H460 cells assessed as cell viability at 50 nM after 48 hrs by MTT assay relative to control2013Journal of natural products, Sep-27, Volume: 76, Issue:9
Antiproliferative cardiac glycosides from the latex of Antiaris toxicaria.
AID471514Cytotoxicity against human HT-29 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471516Cytotoxicity against human CC20 cells after 72 hrs by FMCA method relative to digoxin2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID492114Cardiotonic activity in guinea pig left atrial muscles assessed as minimum positive inotropic effective concentration causing myocardial contraction2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID492118Safety index, ratio of arrhythmogenic concentration to minimum positive inotropic effective concentration causing myocardial contraction in guinea pig left atrial muscles2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID421973Inhibition of HIF1 activation in human U251 cells stably transfected in pGL3 plasmid under hypoxic condition assessed as reduction of luciferase expression at 0.062 uM after 16 to 24 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID1072828Cytotoxicity against human 1A9 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID1072830Cytotoxicity against human U87MG cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID311444Cytotoxicity against human BCG823 cells after 48 hrs by sulforhodamine B assay2007Journal of natural products, Sep, Volume: 70, Issue:9
Cardenolides from Saussurea stella with cytotoxicity toward cancer cells.
AID335137DNA damaging activity against DNA repair-deficient Saccharomyces cerevisiae W303-1A RS188N mutant assessed as drug concentration required to produce 12 mm zone of inhibition up to 800 ug/well by agar diffusion assay1993Journal of natural products, Sep, Volume: 56, Issue:9
A screen for inhibitors of DNA recombination: identification of two new spirostanol glycosides from Chamaedorea linearis.
AID1072831Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID471509Cytotoxicity against human HCT116 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID471512Cytotoxicity against human HCT116 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID421970Growth inhibition of human U251 cells stably transfected with pGL2-TK-HRE plasmid after 24 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421980Reduction in carbonic anhydrase 9 mRNA expression in wild type human U251 cells under hypoxic condition at 0.1 uM after 8 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421979Reduction in VEGF mRNA expression in wild type human U251 cells under hypoxic condition after 16 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID311445Cytotoxicity against human Bel7402 cells after 48 hrs by sulforhodamine B assay2007Journal of natural products, Sep, Volume: 70, Issue:9
Cardenolides from Saussurea stella with cytotoxicity toward cancer cells.
AID492117Cardiotonic activity in guinea pig right ventricular muscles assessed as maximum positive inotropic effective concentration causing myocardial contraction relative to basal level2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID471513Cytotoxicity against human HT-29 cells after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID421974Inhibition of HIF1 activation in human U251 cells transiently transfected in pGL2-TK-HRE plasmid under hypoxic condition at 0.1 to 0.005 uM after 16 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421977Inhibition of HIF1alpha protein expression in wild type human U251 cells under hypoxic condition at 0.025 uM treated 16 hrs before hypoxia induction2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID1072834Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID471508Cytotoxicity against human CC20 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
AID1072825Cytotoxicity against human SK-MEL-2 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID492119Safety index, ratio of arrhythmogenic concentration to minimum positive inotropic effective concentration causing myocardial contraction in guinea pig right ventricular muscles2010Journal of natural products, Jul-23, Volume: 73, Issue:7
Cardiac glycosides from Antiaris toxicaria with potent cardiotonic activity.
AID1072826Cytotoxicity against human HCT9 cells assessed as growth inhibition after 72 hrs by SRB assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Cytotoxic cardiac glycosides and coumarins from Antiaris toxicaria.
AID421972Inhibition of HIF1 activation in human U251 cells stably transfected in pGL2-TK-HRE plasmid under hypoxic condition assessed as reduction of luciferase expression at 0.062 uM after 16 to 24 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID471510Cytotoxicity against human HT-29 cells assessed as survival index at 10 uM after 72 hrs by FMCA method2009Journal of natural products, Nov, Volume: 72, Issue:11
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (52.63)18.7374
1990's5 (6.58)18.2507
2000's3 (3.95)29.6817
2010's21 (27.63)24.3611
2020's7 (9.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.93 (24.57)
Research Supply Index4.53 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.22%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.11%)4.05%
Observational0 (0.00%)0.25%
Other87 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]